Interleukin-2 Receptor alpha Subunit
"Interleukin-2 Receptor alpha Subunit" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A low affinity interleukin-2 receptor subunit that combines with the INTERLEUKIN-2 RECEPTOR BETA SUBUNIT and the INTERLEUKIN RECEPTOR COMMON GAMMA-CHAIN to form a high affinity receptor for INTERLEUKIN-2.
Descriptor ID |
D053645
|
MeSH Number(s) |
D12.776.543.750.705.852.420.320.500
|
Concept/Terms |
Interleukin-2 Receptor alpha Subunit- Interleukin-2 Receptor alpha Subunit
- Interleukin 2 Receptor alpha Subunit
- Antigens, CD25
- CD25 Antigens
- Tac P55 Peptide
- Interleukin-2 Receptor alpha
- Interleukin 2 Receptor alpha
- Receptor alpha, Interleukin-2
- Interleukin-2 Receptor alpha Chain
- Interleukin 2 Receptor alpha Chain
- Interleukin-2 Receptors alpha
- Interleukin 2 Receptors alpha
- Receptors alpha, Interleukin-2
- IL-2Ralpha
- IL 2Ralpha
- Interleukin-2Ralpha
- Interleukin 2Ralpha
- CD25 Antigen
- Antigen, CD25
- alpha-subunit, Receptor, Interleukin-2
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-2 Receptor alpha Subunit".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-2 Receptor alpha Subunit".
This graph shows the total number of publications written about "Interleukin-2 Receptor alpha Subunit" by people in this website by year, and whether "Interleukin-2 Receptor alpha Subunit" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2006 | 0 | 1 | 1 |
2007 | 3 | 1 | 4 |
2008 | 2 | 1 | 3 |
2009 | 1 | 3 | 4 |
2010 | 1 | 2 | 3 |
2011 | 0 | 1 | 1 |
2012 | 0 | 1 | 1 |
2015 | 1 | 1 | 2 |
2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interleukin-2 Receptor alpha Subunit" by people in Profiles.
-
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J Immunother Cancer. 2020 04; 8(1).
-
Premalignant Oral Lesion Cells Elicit Increased Cytokine Production and Activation of T-cells. Anticancer Res. 2016 Jul; 36(7):3261-70.
-
IL-2Ra mediates temporal regulation of IL-2 signaling and enhances immunotherapy. Sci Transl Med. 2015 Oct 28; 7(311):311ra170.
-
Preterm cord blood CD4? T cells exhibit increased IL-6 production in chorioamnionitis and decreased CD4? T cells in bronchopulmonary dysplasia. Hum Immunol. 2015 May; 76(5):329-338.
-
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature. 2012 Mar 25; 484(7395):529-33.
-
A comprehensive analysis of shared loci between systemic lupus erythematosus (SLE) and sixteen autoimmune diseases reveals limited genetic overlap. PLoS Genet. 2011 Dec; 7(12):e1002406.
-
Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A. 2010 Jun 29; 107(26):11906-11.
-
In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med. 2010 Jul; 16(7):809-13.
-
IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proc Natl Acad Sci U S A. 2010 Feb 02; 107(5):2171-6.
-
Comparison of efficacy of induction therapy in low immunologic risk African-American kidney transplant recipients. Transpl Int. 2010 May 01; 23(5):500-5.